GHRP-6: growth hormone booster and appetite stimulant
A synthetic six-amino-acid peptide that triggers the pituitary gland to release growth hormone and strongly stimulates hunger; used only as a lab research tool, not an approved drug.
- Class
- First-generation growth hormone secretagogue; synthetic hexapeptide GHS-R1a agonist
- Status
- No approved indication in any major market; research chemical and compounding compound only
- Best-supported effect
- Pulsatile GH release and pronounced appetite stimulation, characterized across multiple human clinical studies (diagnostic testing, endocrine physiology RCTs); no therapeutic efficacy indication approved or confirmed
- Main caveat
- Human evidence is primarily from diagnostic and physiologic characterization studies, not therapeutic efficacy trials; ipamorelin achieves comparable GH release without cortisol, prolactin, and appetite burden; no approved therapeutic use in any major market
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic six-amino-acid peptide that acts on the ghrelin receptor to trigger the pituitary gland to release growth hormone. It is the original compound of the GHRP class, developed in the 1980s from modification of met-enkephalin analogs by Cyril Bowers and Frank Momany at Tulane University. The stored sequence HWAWFK represents the backbone; the actual drug has two D-amino acids (D-Trp at position 2 and D-Phe at position 5) and a C-terminal amide — modifications that are not visible in the raw one-letter sequence but are essential for receptor potency and metabolic stability. GHRP-6 is not approved for any therapeutic indication in any major market.
History
GHRP-6 emerged from a sustained medicinal chemistry program at Tulane University, where Bowers and Momany observed in the early 1980s that certain met-enkephalin analogs could release GH from pituitary cells, and iterated through short synthetic peptides to retain that activity while stripping away opioid activity. The hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ was the first consistently active compound. For its first decade and a half, GHRP-6 was a pharmacologically orphaned compound: the GHS-R1a receptor was not cloned until 1996, and ghrelin — the endogenous ligand that GHRP-6 mimics — was not identified until 1999. GHRP-6 was investigated in human clinical programs for GH deficiency and short stature through the 1980s and 1990s without achieving regulatory approval. It served as the reference first-generation GHRP against which subsequent compounds — GHRP-2, hexarelin, and ipamorelin — were benchmarked. During the 2000s it migrated into compounding-pharmacy and research-chemical channels, where it is now most often discussed specifically for its appetite-stimulating pharmacology.
What it does
GHRP-6 produces a pulse of growth hormone release from the pituitary, with a co-release of ACTH, cortisol, and prolactin that is intrinsic to its pharmacological profile and cannot be separated from the GH effect at standard doses (Frieboes and colleagues 1995). Its most pharmacologically distinctive feature is strong appetite stimulation: by activating the ghrelin receptor in the hypothalamus, it engages NPY/AgRP pathways that drive hunger. Human studies document that acute appetite stimulation follows injection within approximately 15–60 minutes (peptidelist source). This co-packaged appetite effect distinguishes GHRP-6 from later selective secretagogues such as ipamorelin, which achieve comparable GH release through the same receptor without the cortisol, prolactin, and appetite burden. GHRP-6 also requires endogenous hypothalamic GHRH for maximal GH stimulation — the two signals act synergistically at separate receptors.
Evidence
- Human: Multiple randomized controlled trials and diagnostic clinical studies have characterized GHRP-6's GH, ACTH, cortisol, and prolactin co-response in healthy volunteers and in patients with various endocrine disorders (hypercortisolism, thyrotoxicosis, type 1 and type 2 diabetes, hypothyroidism, Cushing's disease). Frieboes and colleagues (1995, Neuroendocrinology) demonstrated GH, ACTH, and cortisol release with enhanced slow-wave sleep in normal men receiving repeated IV boluses. A pharmacokinetic study in nine healthy male volunteers established the short-acting plasma profile. GHRP-6 has been used as a diagnostic tool for HPA-axis and GH reserve assessment. No controlled efficacy trial for any primary therapeutic indication has been completed.
- Animal: Preclinical rodent studies document cardiac cytoprotection against doxorubicin-induced myocardial damage, renal tissue-repair effects after nephrotoxic injury, and gastric mucosal protective effects. A 2024 study examined GHRP-6 in a hydrogel formulation for acute kidney injury. These animal signals do not have human efficacy trial support.
- In vitro: Assay-level pharmacology consistent with GHS-R1a agonism; IP3/DAG-mediated calcium signaling in pituitary somatotroph cells established.
Known effects
- Pulsatile GH release — Human clinical evidence (multiple RCTs and diagnostic studies; Moderate)
- ACTH and cortisol co-release — Human clinical evidence (intrinsic to pharmacological profile; documented across multiple studies; High)
- Pronounced appetite stimulation — Human clinical and class-level evidence (strong ghrelin-receptor-mediated effect; well-characterized acutely; Strong for mechanism, Moderate for therapeutic application)
- Prolactin elevation — Human clinical documentation (concurrent pituitary pathway; Moderate)
- Slow-wave sleep enhancement — Human clinical (Frieboes and colleagues 1995, Neuroendocrinology; Emerging)
- Cardiac cytoprotection — Preclinical only (rodent models; not established in humans)
- Renal tissue repair — Preclinical only (rodent models; not established in humans)
- Gastric mucosal protection — Preclinical only (not established in humans)
Myths and misconceptions
- "GHRP-6's appetite stimulation is an unwanted side effect" — For some use cases it is the primary pharmacological goal. The appetite effect is a direct consequence of ghrelin-receptor activation in the hypothalamus and is well-characterized in human studies. In cachexia and wasting contexts, hunger induction is the feature, not the bug. Whether it is desirable depends entirely on the clinical context.
- "GHRP-6 is weaker than GHRP-2, so always pick GHRP-2" — GHRP-6 does produce a smaller GH pulse at comparable doses than GHRP-2 or hexarelin, but also produces the strongest appetite stimulation among the characterized GHRPs. The compounds differ in their pharmacological profiles, not simply in potency on a single axis. For appetite-stimulation goals, GHRP-6 is specifically distinguished; for maximal IGF-1 elevation without the cortisol and appetite burden, GHRP-2 or ipamorelin may be more appropriate.
- "GHRP-6 is FDA-approved because it has been studied since the 1980s" — Duration of research interest is not regulatory approval. GHRP-6 has been studied for more than 40 years without achieving approval in any major market.
- "GHRP-6 is undetectable in anti-doping tests" — LC-MS/MS urinary detection methods for GHRP-6 and its metabolites are well-established in WADA-accredited laboratories. Short plasma half-life does not equal undetectability.
Safety signals
- Pronounced appetite stimulation: Intrinsic ghrelin-receptor-mediated effect; acute onset within approximately 15–60 minutes of injection per human study characterization; does not fully tolerize with continued use at standard doses per available data.
- Cortisol and ACTH co-release: Documented across multiple human RCTs and diagnostic clinical trials; intrinsic to GHRP-6's pharmacological profile and not separable from the GH effect at standard doses.
- Prolactin elevation: Documented in human clinical studies; magnitude and clinical consequences of chronic exposure not established in long-term trials.
- Water retention: Reported as a clinical and community signal; mechanism not separately characterized in source.
- Glucose and insulin interaction: GH opposes insulin action; cortisol elevation further antagonizes glycemic control; the combined appetite-stimulating effect creates additional metabolic consideration in populations with diabetes or insulin resistance.
- Long-term HPA-axis and reproductive-endocrine consequences: Whether cortisol and prolactin elevation at chronic doses over months produces clinically meaningful consequences has not been characterized in controlled studies — identified as a key evidence gap.
Regulatory status
- US (FDA): Not approved for any indication. Historically available through compounding pharmacies under individualized prescription; the FDA's 503A bulk-list review has challenged compounding access for GH secretagogues including GHRP-6. Sold in the research-chemical market labeled "not for human consumption" — not an authorized channel for human use.
- EU (EMA): Not authorized.
- UK (MHRA): Not authorized.
- Australia (TGA): GH secretagogues classified as Schedule 4 prescription-only substances per source.
- Canada: Unapproved investigational agent.
- WADA: Prohibited at all times under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. LC-MS/MS urinary detection methods well-established in accredited laboratories.
Mechanism
GHRP-6 is a potent agonist of the GHS-R1a receptor (ghrelin receptor), expressed in pituitary somatotrophs and in hypothalamic nuclei. In pituitary cells, receptor activation triggers IP3/DAG-mediated calcium signaling, promoting pulsatile GH secretion. Hypothalamic GHS-R1a activation engages NPY/AgRP neurons, producing the pronounced appetite stimulation that is pharmacologically inseparable from GH release at therapeutic doses. GHS-R1a activation also drives ACTH release, producing co-incident cortisol elevation; prolactin rises concurrently through a separate pituitary pathway. Source human studies establish that GH, ACTH, cortisol, and prolactin responses occur together and are not individually separable at standard doses.
GHRP-6 also requires intact endogenous hypothalamic GHRH signaling for maximal GH stimulation — the two signals act synergistically at separate receptors (GHS-R1a for GHRP-6 and the GHRH receptor for GHRH analogs). This synergy is the basis for combined GHRP + GHRH analog use in research contexts.
The full amino-acid sequence is His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (MW 873.01 Da). The D-configuration at positions 2 and 5 and the C-terminal amide are essential for receptor binding and metabolic stability; the stored 1-letter sequence HWAWFK does not represent these modifications.
Compared to ipamorelin — which acts at the same receptor — GHRP-6 produces more robust cortisol, prolactin, and appetite responses, consistent with GHS-R1a agonism that also engages corticotroph and lactotroph pathways. Hexarelin, structurally similar (D-2-methyl-Trp substitution at position 2), has been reported to produce comparable or greater GH release in comparative studies (Imbimbo and colleagues 1994, Eur J Clin Pharmacol).
Preclinical studies describe additional pharmacology beyond the GH-appetite axis: cardiac cytoprotective effects against doxorubicin-induced myocardial damage, renal tissue-repair signals in rodent models, and gastric mucosal protective effects. These preclinical signals do not have human efficacy trial support.
Open questions
- Human cachexia/wasting efficacy: The appetite-stimulation use case most frequently discussed for GHRP-6 has not been tested in a modern placebo-controlled trial in wasting or cachexia populations. The mechanism is well-characterized but the therapeutic endpoint in this population is unvalidated.
- Chronic HPA-axis and reproductive-endocrine consequences: Whether GHRP-6's cortisol and prolactin elevation at chronic doses over months produces clinically meaningful consequences has not been characterized in controlled studies.
- Long-term human safety: Long-term (>12 month) safety data outside diagnostic-test and acute-challenge populations is essentially absent from available literature.
- Preclinical translation — cardiac and renal signals: Whether cardiac cytoprotective and renal-repair preclinical signals translate to any human clinical outcome has not been tested.
- Head-to-head comparative trials: Direct comparisons between GHRP-6 and GHRP-2 or ipamorelin on long-duration body-composition and functional endpoints in non-deficient adults are absent.
Related peptides
- GHRP-2 — Second-generation GHRP; acts at the same GHS-R1a receptor with greater GH-releasing potency and less appetite stimulation than GHRP-6.
- Ipamorelin — Selective GHS-R1a agonist; produces GH release without the cortisol, prolactin, and appetite co-response seen with GHRP-6; considered the cleaner secretagogue for GH-release goals.
- Hexarelin — Structural analog of GHRP-6 (D-2-methyl-Trp at position 2); compared directly to GHRP-6 in human studies (Imbimbo and colleagues 1994); generally reported as more potent on GH release.
- MK-677 (ibutamoren) — Non-peptide oral GHS-R1a agonist; activates the same receptor as GHRP-6 with oral bioavailability and a longer half-life.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does GHRP-6 turn on the stress-hormone gene in pituitary cells through its own pathway, not just as a side effect of releasing growth hormone?
If the stress-axis effect is a separate, switchable mechanism, it might be possible to design next-generation versions of GHRP-6 that release growth hormone without triggering cortisol, making them safer for long-term use in children and adults with growth hormone deficiency.
Does the natural-amino-acid form of GHRP-6 partially block the hunger/growth-hormone receptor instead of activating it?
If true, a simpler, cheaper-to-make version of the peptide could be used to dial down appetite signaling without triggering a full growth hormone surge, which could matter for people managing obesity or metabolic disease.
Would attaching a fatty-acid chain to the end of GHRP-6 let it form a slow-dissolving depot under the skin and release growth hormone gradually?
If this works, patients who currently need multiple daily injections to maintain growth hormone levels could potentially switch to less frequent dosing, improving quality of life and reducing cortisol spikes that come from high peak drug levels.
Can GHRP-6, given in timed pulses during sleep, keep stimulating growth hormone release night after night without losing effect?
If true, older adults with reduced growth hormone pulsatility might benefit from a nightly regimen aimed at supporting lean muscle and bone, without daily growth hormone injections, which carry higher cost and side-effect risk.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9683195352554321 | boltz-2 |
| ranking score | 0.838910698890686 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.675 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10761,
sequence = {HWAWFK},
target = {ghsr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}